文献速递头颈部肿瘤放疗放疗物理与技术

头颈部肿瘤螺旋断层放疗中自适应放疗必要性的研究

Investigating the necessity of adaptive radiotherapy in tomotherapy of head and neck cancer patients.
PubMed 文献 · Radiat Oncol · 2025-07-21

本研究回顾性分析58例头颈部肿瘤患者 helical tomotherapy 的1740幅MVCT图像,评估不同治疗部位关键解剖结构的体积和剂量变化,以确定各部位需要自适应放疗的患者比例。结果显示并非所有患者都需要ART,口腔癌、喉癌和鼻咽癌患者中分别最多有10.53%、28.57%和18.18%需要ART,唾液腺癌患者不需要ART。结论提示选择ART候选患者时应考虑体重下降和肿瘤快速缩小等因素。

要点

  • 头颈部肿瘤患者中并非所有患者都需要自适应放疗。
  • 口腔癌、喉癌、鼻咽癌需ART比例分别最多为10.53%、28.57%、18.18%。
  • 唾液腺癌患者不需要ART。

核心结论

  • 虽然监测放疗过程中肿瘤和危及器官的体积与剂量变化很重要,但并非所有头颈部肿瘤患者都需要自适应放疗。
  • 选择ART候选患者时应考虑体重下降和肿瘤快速缩小等标准,CT模拟与首次治疗的时间间隔也起重要作用。

研究设计与样本

  • 回顾性研究,共纳入58例接受螺旋断层放疗的头颈部肿瘤患者,导出1740幅兆伏级CT图像至PreciseART™软件进行分析。
  • 计算计划阶段、首次和末次治疗时计划靶区和危及器官的体积变化,并通过实际累积剂量与初始计划剂量的差异判断哪些患者从ART中获益。

主要发现

  • 所有患者计划阶段与首次治疗之间的平均体积变化:PTV为3.93%,脑干为4.49%,脊髓为6.46%。
  • 所有患者首次与末次治疗之间的平均体积变化相对较小:PTV为0.84%,脑干为3.62%,脊髓为1.19%。
  • 所有患者末次治疗时初始计划剂量与实际累积剂量的平均剂量变化范围:脑干为10.43-30.81%,左腮腺为4.66-11.61%,右腮腺为3.73-9.97%,脊髓为-0.17-5.40%。
  • 口腔癌、喉癌和鼻咽癌患者中分别最多有10.53%、28.57%和18.18%需要ART,唾液腺癌患者不需要ART。

关键数值与推荐

  • 口腔癌患者中最多10.53%需要ART。
  • 喉癌患者中最多28.57%需要ART。
  • 鼻咽癌患者中最多18.18%需要ART。
  • 唾液腺癌患者不需要ART。

临床怎么用

  • 头颈部肿瘤放疗中应监测肿瘤和危及器官的体积与剂量变化,但不应默认所有患者均需ART。
  • 选择ART候选患者时可考虑体重下降和肿瘤快速缩小等因素,并关注CT模拟与首次治疗的时间间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anatomical variations that occur during radiation therapy in head and neck cancer (HNC) patients can lead to significant dosimetric changes. The purpose of this study is to evaluate dosimetric and volume changes in key anatomical structures for different treatment sites in HNC patients, and to determine the percentage of patients who need adaptive radiotherapy (ART) per treatment site. METHODS: A total of 1,740 megavoltage computed tomography (MVCT) images from 58 HNC patients treated with helical tomotherapy (HT) were exported to the PreciseART™ (Accuray) software. Volume changes in the planning target volume (PTV) and the organs at risk (OARs) in the planning stage and the first and last fractions of treatment were calculated. The differences between the values of actual accumulated and initial plan doses were used to determine which patients benefit ART. RESULTS: The average volume changes between the planning stage and the first fraction were 3.93%, 4.49%, and 6.46% for the PTV, brainstem, and spinal cord, respectively, for all patients. However, the average volume changes between the first and last fractions of treatment were relatively small and included 0.84%, 3.62%, and 1.19% for the PTV, brainstem, and spinal cord, respectively. The average dose changes between the initial planned dose and the actual cumulative dose in the last fraction were in the range of 10.43-30.81%; 4.66-11.61%; 3.73-9.97%; and - 0.17-5.40% for the brainstem, left parotid, right parotid, and spinal cord, respectively, for all patients. A maximum of 10.53%, 28.57%, and 18.18% of patients with oral cavity, larynx, and nasopharyngeal cancers, respectively, needed ART. Patients with salivary gland cancers did not need ART. CONCLUSION: Although monitoring the volume and dose changes of the tumor and OARs during the course of radiation therapy is important, not all patients need ART. Criteria such as weight loss and rapid tumor shrinkage should be considered when selecting candidate patients for ART. The time interval between CT simulation and the first fraction also plays an important role in the difference in the volume and dose to organs during the course of radiation therapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chaparian A, Kianinia M, Roayaei M, et al. Investigating the necessity of adaptive radiotherapy in tomotherapy of head and neck cancer patients. Radiat Oncol. 2025. PMID: 40691612. doi:10.1186/s13014-025-02689-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。